[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"kidney-tumor\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:kidney-tumor":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,73,96,136],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100629851","a-phase-ii-clinical-two-stage-study-of-transcranial-magnetic-stimulation-in-preventing-postoperative-delirium-in-elderly-patients-after-urological-surgery-100629851",false,"NCT07480044","A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly Patients After Urological Surgery","Inclusion Criteria:(1) Age ≥ 60 years old; (2) Patients scheduled for elective urological surgery under general anesthesia with tracheal intubation; (3) ASA classification I - III; (4) Estimated operation duration ≥ 2 hours; (5) Informed consent from the patient or their guardian; (6) Proficient in communicating in Chinese. -\n\nExclusion Criteria:(1) Patients with permanent lack of autonomy (2) Not applicable for delirium assessment: including language disorders, deafness, blindness or aphasia, coma (3) With treatment abandonment or brain death (4) Known pregnancy or lactation (5) Unable to obtain consent according to national regulations (6) Patients forcibly hospitalized by regulatory authorities (compulsory measures) (7) With cardiac pacemaker or stent implantation (8) Patients with delirium (9) Patients with known brain lesions (10) Patients with known epilepsy history, having taken drugs that can cause epileptic seizures, having metal implants in the neck or brain, or having cerebral hemorrhage ，Acute phase, acute infectious diseases (11) Habitual treatment with antipsychotic drugs (12) Received antipsychotic drug treatment in the ICU before enrollment (13) Patients with severe liver dysfunction (Child-Pugh C grade) (14) Patients with severe kidney dysfunction (requiring dialysis before surgery) (15) Severe heart failure (METS \\\u003C 4) (16) Preoperative cognitive impairment as determined by a MoCA evaluation prior to surgery;\n\n\\-","ALL","60 Years",{"count":18,"type":19},220,"ESTIMATED","INTERVENTIONAL",[22],"NA","Cases were included based on the inclusion and exclusion criteria, and induction, maintenance, and recovery were conducted in accordance with the standard protocol for general anesthesia. After tracheal intubation and before tracheal tube removal at the end of the surgery, the parameters for iTBS stimulation frequency and duration were as follows: intensity was 80% of the active movement threshold, with 3 pulses per cluster at 50Hz, a frequency of 5Hz, 30 clusters of 10 pulses each, an 8 - second interval, and a single 600 - pulse; the 8 - shaped coil was connected to the electrodes in the designated head area (left frontal lobe cortex).Observation contents: Whether there is postoperative delirium and its severity: 3D - CAM assessment scale, DMAS assessment scale; awakening time, extubation time, PACU stay time, hospital stay time; 1 - 7 days after surgery or before discharge, POD assessment and pain - sleep assessment, the first time getting out of bed; postoperative complications; adverse reactions; adverse events, and so on.",[25,26,27],"Postoperative Delirium (POD)","Prostate Cancer","Kidney Tumor",[29,30,31],"Transcranial Magnetic Stimulation Device","elderly patients","Postoperative Delirium","NOT_YET_RECRUITING","2026-03-13",{"date":35,"type":36},"2026-03-18","ACTUAL",{"date":38,"type":19},"2026-03-20",{"date":40,"type":19},"2028-12-01",{"name":42,"class":43},"Zhejiang University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":20,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100507699","engineering-immune-organoids-to-study-pediatric-cancer-100507699","NCT05890781","Engineering Immune Organoids to Study Pediatric Cancer","Engineering Immune Organoids to Study Pediatric Cancer (IMMUNE-ORGANOIDS)","IMMUNEORGANOID","Inclusion Criteria:\n\n* Age at diagnosis ≤ 25 years except for patients with malignant gliomas and renal tumors for whom no upper age limit is applied\n* Medical suspicion or diagnosis of one of the following diseases, regardless of stage:\n* Brain tumors\n* Renal tumors\n* Neuroblastoma\n* Sarcomas\n* Adult patient or parents or guardians should understand, sign and date the appropriate written informed consent from prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol.\n* Affiliated to a social security system or beneficiary of the same.\n\nExclusion Criteria:\n\n* Any histology not mentioned in the inclusion criteria\n* Adult patient or parents\u002Fguardians incapable\u002Fincapable of giving its\u002Ftheir consent\n* Patients deprived of their liberty by a judicial or administrative decision","25 Years",{"count":55,"type":19},108,[22],"To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)",[59,27,60,61],"Brain Tumor","Neuroblastoma","Sarcoma","RECRUITING","2026-02-05",{"date":65,"type":36},"2026-02-09",{"date":67,"type":36},"2023-05-12",{"date":69,"type":19},"2028-05",{"name":71,"class":43},"Gustave Roussy, Cancer Campus, Grand Paris",2,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":15,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":20,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":44},"100469058","decision-aid-da-for-renal-patients-100469058","NCT05387863","Decision Aid (DA) for Renal Patients","Evaluation of a Decision Aid in the Treatment Planning of Small Renal Tumors","Inclusion Criteria:\n\n* Male and female post-op and pre-op patients, ages 18 and older, diagnosed with a localized renal tumor up to 4 cm in diameter.\n* Patients scheduled for standard-of-care clinical exams with the NYU Urology Department\n\nExclusion Criteria:\n\n* Stage IV cancer of any type\n* Inability to provide informed consent\n* Vulnerable subjects will not be recruited","18 Years",{"count":82,"type":19},40,[22],"The objective of this study is to understand how patients make decisions about treating their kidney masses, and to identify key values and preferences for treating their kidney masses. The study team will develop a decision aid (DA) using the decision-analytic model to communicate personalized benefit\u002Fharm estimates to patients and promote patient-centered treatment of renal tumors.",[27,86],"Renal Cancer","2025-11-28",{"date":89,"type":36},"2025-12-02",{"date":91,"type":36},"2022-09-12",{"date":93,"type":19},"2026-09",{"name":95,"class":43},"NYU Langone Health",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":15,"minAge":103,"maxAge":104,"enrollmentInfo":105,"targetDuration":4,"studyType":20,"phases":107,"briefSummary":110,"conditions":111,"keywords":118,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":44},"100597051","phase-1-crispr-edited-hla-donor-kidney-transplant-to-reduce-rejection-risk-100597051","NCT07053462","CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk","Phase 1\u002F2, Single-Arm, Open-Label Trial to Evaluate the Safety, Feasibility, and Immunogenicity of Ex Vivo CRISPR-Cas9 Gene-Edited Donor Kidneys (Knockout of HLA-A, HLA-B, and CIITA) in Human Renal Transplant Recipients","Inclusion Criteria:\n\n* Adult patients, age 16 to 85 years, with end-stage renal disease (ESRD) who are candidates for kidney transplantation. This includes patients on dialysis or approaching dialysis who have been evaluated and listed for transplant.\n* Eligible for transplant surgery based on medical assessment (i.e., no contraindications to major surgery and transplantation). The patient's overall health status must be sufficient to undergo the transplant procedure and the required immunosuppression.\n* Suitable donor organ available: A deceased-donor kidney that meets standard acceptable criteria for transplant (e.g., adequate organ function and anatomy) and is ABO blood type compatible with the recipient. The donor kidney must be allocated to the trial and available for ex vivo gene editing prior to transplantation.\n* Informed consent: The patient (or legally authorized representative) is able to understand the experimental nature of the study and has voluntarily signed the informed consent form. The patient must be willing to comply with all study procedures, follow-up visits, and laboratory tests.\n* Negative crossmatch (if applicable): No pre-existing anti-donor reactivity that would cause immediate graft failure. (All recipients should have a negative T and B cell crossmatch with the donor organ prior to transplant, as per standard practice, to ensure no strong baseline donor-specific antibodies, especially against any remaining donor HLA such as HLA-C.)\n* Women of childbearing potential must have a negative pregnancy test and must agree to use effective contraception during the study and for a period after (to be specified, e.g., 1 year post-transplant), given the use of immunosuppressants and the unknown effects of gene-edited organ transplantation on pregnancy. Men with partners of childbearing potential should also agree to use contraception.\n* High immunologic risk patients are eligible: Patients with high panel reactive antibody (PRA) levels or a history of sensitization (from prior transplants, blood transfusions, or pregnancies) are allowed and even anticipated in this trial, as the intervention is designed to benefit patients with broad HLA sensitization. For instance, patients with calculated PRA \\> 80% (who have difficulty finding matched donors) can be included. (Such patients must still meet the crossmatch criterion above - any existing antibodies should not target the antigens remaining on the edited graft.)\n* Geographic availability: Patients must be available for long-term follow-up in the study center in China or able to travel for scheduled follow-up visits. They should be willing to remain in proximity to the transplant center for the initial post-operative period as per standard transplant care.\n\nExclusion Criteria:\n\n* Active infection: Any ongoing severe infection that would contraindicate transplantation or be exacerbated by immunosuppression (e.g., active tuberculosis, untreated Hepatitis B or C, HIV with uncontrolled viremia, etc.). Patients with controlled HIV (on stable antiretroviral therapy with undetectable viral load) may be considered on a case-by-case basis, but active uncontrolled infection is excluded.\n* Pregnancy or breastfeeding: Pregnant women are excluded due to the need for immunosuppressive drugs and the unknown risks of the investigational intervention on a fetus. Women who are breastfeeding are also excluded due to potential drug excretion in milk and unknown risks to the infant.\n* Multi-organ transplant need: Patients requiring more than one organ transplant simultaneously (e.g., kidney + liver, or kidney + heart) are excluded, as this trial focuses on isolated kidney transplant outcomes. (A history of a prior transplant is not an automatic exclusion if the patient now only needs a kidney, but concurrent multi-organ requirements are excluded.)\n* Severe co-morbidities that would significantly increase transplant risk or confound results: for example, uncontrolled cardiovascular disease (e.g., recent myocardial infarction, severe heart failure), uncontrolled diabetes with end-organ damage beyond ESRD, severe liver dysfunction, or other life-threatening illnesses unrelated to kidney failure. Such conditions could make the surgery unsafe or the outcome hard to interpret.\n* Contraindications to immunosuppression: Patients with conditions that preclude standard immunosuppressive therapy (for instance, a history of anaphylaxis to tacrolimus or mycophenolate that cannot be managed, or chronic infection that would be fatally worsened by immunosuppression) are excluded. The trial still relies on baseline immunosuppressants, so patients must be able to tolerate them.\n* Inability to follow the protocol: Patients with significant psychiatric disorders, cognitive impairment, or social situations that would make adherence to the study protocol and follow-up unlikely. This includes inability to give informed consent or lack of support for the intensive follow-up (for example, if the patient is incarcerated or has no fixed address, etc.).\n* Prior gene therapy or organ experiment participation: Patients who have previously received any investigational gene therapy, or who have a donor-specific tolerance induction or other experimental transplant treatments ongoing, may be excluded to avoid confounding effects. (This is a precaution to attribute outcomes specifically to the CRISPR-edited organ intervention.)\n* Laboratory abnormalities: Any clinically significant abnormalities in baseline labs that would pose added risk - for instance, severe leukopenia or thrombocytopenia that could worsen with immunosuppression, or uncontrolled coagulopathy that raises surgical risk.\n* Donor-related exclusions: If the donor kidney, upon retrieval, is found unsuitable for gene editing or transplant (e.g., poor organ quality, unexpected disease in the organ, or if the CRISPR editing fails to achieve sufficient knockout of target genes), the transplant to that patient will not proceed under the study (the patient may either receive a standard transplant off-study or wait for another opportunity). In such a case, the patient might be withdrawn or deferred, but this is a procedural consideration rather than a characteristic of the patient.","16 Years","85 Years",{"count":106,"type":19},90,[108,109],"PHASE1","PHASE2","This clinical trial investigates the transplantation of donor kidneys that have been genetically modified ex vivo using CRISPR-Cas9 genome editing to reduce immunogenicity and transplant rejection. Donor kidney grafts will have key human leukocyte antigen (HLA) genes disrupted - specifically, knockout of HLA class I heavy chains HLA-A and HLA-B, along with disabling HLA class II expression by targeting the CIITA gene (a master regulator of HLA-DR\u002FDQ\u002FDP). Approximately 90 adult end-stage renal disease patients will receive a CRISPR-edited donor kidney transplant. The primary objectives are to assess the safety and feasibility of this novel intervention, while secondary objectives evaluate the reduction in immune responses (immunogenicity), graft function, and the practicality of implementing ex vivo gene-edited organ transplantation in humans. By knocking out major donor HLA molecules, the trial aims to reduce T-cell and antibody-mediated recognition of the graft, potentially lowering rejection rates and reliance on high-dose immunosuppressants. Safety, including any off-target effects or unanticipated immune reactions, will be closely monitored, and transplant outcomes will be tracked for one year post-transplant.",[112,113,114,115,27,116,117],"End-Stage Renal Disease","End Stage Renal Disease on Dialysis","End Stage Renal Disease With Renal Transplant","Kidney Transplant Rejection","Kidney Failure","Kidney Ischemia",[119,120,121,116,122,123,124,125,126],"HLA Mismatch Immunogenicity","Transplant Rejection (Immunologic)","Kidney Transplantation (Allograft)","CRISPR-Cas9","Kidney Transplant","Human Leukocyte Antigen (HLA)","Immunogenicity Reduction","Graft Rejection Prevention","2025-06-26",{"date":129,"type":36},"2025-07-08",{"date":131,"type":36},"2025-06-01",{"date":133,"type":19},"2028-12-28",{"name":135,"class":43},"AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":142,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":15,"minAge":80,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":147,"conditions":148,"keywords":151,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":44},"100495267","renal-mass-biopsy-peer-and-99mtc-sestamibi-spectct-for-patients-with-clinically-localized-renal-tumors-100495267","NCT05728957","Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT\u002FCT for Patients With Clinically Localized Renal Tumors","A Prospective Diagnostic Cohort Study to Compare the Accuracy of Renal Mass Biopsy, PEER, and 99mTc-sestamibi SPECT\u002FCT for Patients With Clinically Localized Renal Tumors","BIOPSy","Inclusion Criteria:\n\n* Participants diagnosed with a clinically localized (cT1) renal tumor ≤7cm in size with a solid component suspicious for malignancy based on cross-sectional imaging\n* Pre-existing CT images of the mass with and without contrast or planned CT to ensure both with and without contrast images of the mass have been obtained within a 365-day window\n* Participants must be greater than or equal to 18 years of age\n* Eligible or planned to undergo partial or radical nephrectomy as determined by primary urologist\n* Eligible or planned to receive renal mass biopsy as determined by primary urologist\n* Estimated glomerular filtration rate of ≥30 ml\u002Fmin\u002F1.73 m2 as calculated by the CKD-EPI (Chronic Kidney Disease-Epidemiology Collaboration) Equation\n\nExclusion Criteria:\n\n* Participants must not be pregnant (as determined by local policy by radiology \u002F imaging center)\n* Participants must not have evidence of clinical nodal or distant metastasis.\n* Participants must not have had a history of other malignancy with concern for renal metastasis.\n* Participants must not have any known allergy to technetium or sestamibi.",{"count":145,"type":19},100,"OBSERVATIONAL","The goal of this clinical trial is to better tell apart whether kidney tumors are benign (not cancer) or malignant (cancer) based on a biopsy or imaging tests and ask patients how they feel about decisions they make about treatment of their kidney tumor.\n\nThe main objectives are:\n\nTo estimate and compare the diagnostic accuracy of renal mass biopsy alone, PEER (with renal mass biopsy), and 99mTc-sestamibi SPECT\u002FCT (with renal mass biopsy for hot tumors) to differentiate malignant and benign renal tumors.\n\nTo estimate and compare the diagnostic accuracy of renal mass biopsy, PEER (with renal mass biopsy), and 99mTc-sestamibi SPECT\u002FCT (with renal mass biopsy for hot tumors) to differentiate oncocytoma from chromophobe RCC.\n\nParticipants will be asked to complete survey questions related to their health and kidney tumor at the start and end of the study. These can be done on paper, electronically, or by telephone.",[27,149,150],"Renal Benign Neoplasm","Renal Malignant Tumor",[27,152,153,154,149,150,155,156],"Survey Questions","Benign","Malignant","Nuclear Imaging","Computed Tomography","2025-03-17",{"date":159,"type":36},"2025-03-19",{"date":161,"type":36},"2023-02-01",{"date":163,"type":19},"2033-12",{"name":165,"class":43},"Loyola University"]